Semaglutide: STEP Trials, SELECT Cardiovascular Outcomes, and the Compounding Landscape

Semaglutide is the most clinically validated weight-loss compound in modern medicine. That's not a marketing line — it's what the trial record actually looks like when you read it end to end. The STEP program mapped out the weight loss in real populations. The SELECT trial proved the cardiovascular benefit. And the compounding story that dominated headlines for two solid years has largely closed out now that the FDA-recognized shortage has ended. I want to walk through all three honestly.

For where semaglutide fits in the broader GLP-1 class — including how it compares to tirzepatide, retatrutide, and CagriSema — see the GLP-1 peptides class guide. This deep dive stays focused on what the semaglutide trial data actually shows, the cardiovascular outcomes story, the side effects conversation, and what happened to the compounded supply chain.

I have been following the GLP-1 space since the early liraglutide days. Semaglutide is not perfect — the side effect profile is real, the muscle loss question matters, and tirzepatide has now surpassed it in direct head-to-head data (SURMOUNT-5, NEJM 2025). But it remains the compound with the most extensive safety and efficacy record in the class, and the only one with proven cardiovascular outcomes.

How semaglutide works

GLP-1, or glucagon-like peptide-1, is a hormone your gut produces naturally after you eat. It does three things simultaneously: signals your brain that you are full, tells your pancreas to release insulin in response to glucose, and slows gastric emptying so nutrients are absorbed more gradually.

The natural version has a half-life of about two minutes. Your body breaks it down almost immediately through an enzyme called DPP-4. That is where semaglutide gets clever.

Semaglutide is a modified version of natural GLP-1 with two key structural changes. An amino acid substitution at position 34 makes it resistant to DPP-4 degradation. A C-18 fatty acid chain allows it to bind to albumin in your blood, dramatically extending circulation time. The result is a half-life of approximately seven days — long enough for once-weekly dosing. Going from a two-minute molecule to a seven-day molecule while preserving receptor specificity and biological activity took Novo Nordisk decades of medicinal chemistry.

Once semaglutide binds to GLP-1 receptors in the hypothalamus, it reduces appetite through several converging pathways. It activates POMC/CART neurons (which suppress hunger) and inhibits NPY/AgRP neurons (which stimulate hunger). It also appears to modulate the mesolimbic reward pathway, reducing the hedonic drive to eat — which is why many people on semaglutide report not just eating less, but genuinely thinking about food less.

The gastric emptying effect extends post-meal satiety. You feel full longer after a smaller meal. Combined with central appetite suppression, the result is typically a 20-35% reduction in caloric intake without conscious restriction.

The STEP trials

The STEP clinical trial program is one of the most comprehensive datasets in obesity medicine — multiple large, randomized, double-blind, placebo-controlled trials across different populations.

STEP 1 enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity, none with diabetes. At 68 weeks on semaglutide 2.4mg weekly, average weight loss was 14.9% compared to 2.4% on placebo. About one-third of participants lost more than 20% of their body weight.

STEP 2 focused on people with type 2 diabetes and obesity. Weight loss was more modest at 9.6%, which is expected because diabetes medications and metabolic dysfunction attenuate weight-loss responses. But the glycemic improvements were substantial — HbA1c dropped 1.6 percentage points.

STEP 3 added intensive behavioral therapy on top of semaglutide and produced 16.0% weight loss, suggesting lifestyle support amplifies the pharmacological effect. STEP 4 asked what happens when you stop: participants switched from semaglutide to placebo after 20 weeks regained about two-thirds of their lost weight over the following 48 weeks. This tells us semaglutide is managing a chronic condition, not providing a one-time fix — consistent with the emerging understanding of obesity as a chronic neuroendocrine disorder.

STEP 5 provided the longest follow-up at 104 weeks of continuous treatment. Average weight loss was 15.2% at two years, with no plateau-and-bounce pattern. Participants maintained clinically significant weight loss for the full study duration.

Across the program, the headline number is roughly 16.9% average weight loss at the 2.4mg dose — about three to four times what any previous FDA-approved weight-loss medication achieved.

The SELECT trial and cardiovascular outcomes

If the STEP trials established weight-loss efficacy, SELECT established something arguably more important.

SELECT enrolled over 17,600 participants aged 45 and older with established cardiovascular disease and overweight or obesity, but without diabetes. The results, published in the New England Journal of Medicine in 2023, showed a 20% relative risk reduction in the primary composite endpoint — cardiovascular death, nonfatal heart attack, or nonfatal stroke. Absolute risk reduction was 1.5 percentage points over a median follow-up of 39.8 months.

This matters for several reasons. It demonstrates cardiovascular benefits beyond the diabetes population. The 20% risk reduction is comparable to statins. And it makes a compelling case that obesity treatment itself reduces cardiovascular risk, independent of diabetes management. The mechanism is likely multifactorial — semaglutide reduces weight, systemic inflammation, and improves lipid profiles and blood pressure, and may have direct anti-atherosclerotic effects on vessel walls. The cardiovascular benefit appears to exceed what weight loss alone would predict.

Oral vs. injectable

Most people associate semaglutide with weekly injections, but Novo Nordisk also developed an oral formulation marketed as Rybelsus for diabetes. The oral version uses a permeation enhancer called SNAC that protects semaglutide from stomach acid and promotes absorption through the gastric lining.

It works, but with caveats. Bioavailability is roughly 1%, meaning 99% of the oral dose never reaches the bloodstream. The PIONEER trial program showed meaningful results with higher nominal tablet doses, but effect sizes were generally smaller than the injectable version. Oral semaglutide also has strict administration requirements set by the FDA label — those are part of the provider/pharmacy conversation, not something to figure out from a guide.

Injectable semaglutide remains more potent and more predictable. The oral form is an option for people who strongly prefer not to inject, but it comes with trade-offs.

Dosing escalation

In clinical settings, semaglutide dosing follows a gradual escalation designed to minimize gastrointestinal side effects. The specific titration schedule is set by the FDA label and managed by the prescribing physician.

For weight management, the FDA-approved target is 2.4mg weekly (Wegovy). For type 2 diabetes, it is 1.0mg or 2.0mg weekly (Ozempic). Many people receiving semaglutide for diabetes are on lower doses than those studied for weight management.

The dose-response relationship is well characterized — higher doses produce greater weight loss but also more side effects. The escalation protocol exists because starting at full dose causes unacceptable nausea in a substantial percentage of people. Patience with the ramp genuinely pays off.

How semaglutide stacks up against the rest of the class

The short version: semaglutide is no longer the most potent compound in the GLP-1 class for weight loss alone, but it remains the compound with the most extensive safety record and the only one with proven cardiovascular outcomes.

In SURMOUNT-5 (NEJM, May 2025), the first direct head-to-head trial in obesity, tirzepatide produced -22.8 kg of weight loss versus semaglutide's -15.0 kg over 72 weeks. That's a meaningful gap that confirmed years of cross-trial signal pointing the same direction. CagriSema (REDEFINE 1) and retatrutide (Phase 2) have shown comparable or larger weight loss magnitudes against semaglutide as well — though both are still investigational.

But the cardiovascular outcomes data is where semaglutide still leads. SELECT showed a 20% relative reduction in heart attacks, strokes, and cardiovascular death in adults who had established cardiovascular disease and obesity but no diabetes. Tirzepatide's SURPASS-CVOT showed it doesn't increase cardiovascular risk, but the trial wasn't set up to prove a benefit the way SELECT was. And the newer compounds — retatrutide, CagriSema — don't have cardiovascular outcomes trials read out yet at all.

If you are evaluating these compounds on weight loss alone, semaglutide no longer leads. If you are evaluating them on the totality of evidence — safety, durability, cardiovascular outcomes, real-world experience — semaglutide still has the most complete record. For the full class comparison with all four compounds, see the GLP-1 peptides class guide.

What happened to the compounding landscape

The compounded semaglutide story is essentially a two-year regulatory cycle that's now closing. Worth walking through because the cultural moment around "$129/month online GLP-1" was built on a window that has largely shut.

Here's the regulatory mechanism that made it possible. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to produce versions of drugs that the FDA has officially declared in shortage. When the FDA put semaglutide on that list during 2022-2023, 503A and 503B compounding pharmacies started making it — often at a fraction of what Novo Nordisk's branded versions cost. Most of the compounded product wasn't quite the same molecule, though: it was semaglutide sodium or semaglutide acetate, salt forms that are chemically distinct from the semaglutide base in Wegovy and Ozempic. The FDA spent the entire shortage saying those salt forms hadn't been shown to be equivalent to the approved drug, and there were active legal and regulatory fights the whole time over whether and how the compounding could continue.

The FDA declared the shortage resolved in 2025, and that pulled the 503A floor out from under mass compounding. Through late 2025 and into 2026 the agency actively closed the window, and reporting from Pharma Times confirms the era of widely available compounded semaglutide is effectively over for most patients. Narrow clinical-need exceptions are still allowed — a prescriber can document specific circumstances that justify a compounded formulation — but the broad telehealth-plus-low-price ecosystem that exploded during the shortage is largely gone.

What this means practically: the millions of patients who used compounded semaglutide during the shortage window represent a significant body of real-world experience, much of it broadly consistent with the branded product's expected effects. But that experience was accumulated under conditions without rigorous stability, sterility, or potency testing — and the FDA has issued explicit warnings about fraudulent compounded products that contain false labeling, dangerous impurities, or salt forms not authorized for compounding. The Novo Nordisk medical affairs position is that compounded "semaglutide" is not FDA-approved and has not been reviewed for safety, effectiveness, or quality.

The compounding saga reshaped expectations about peptide access more broadly. For semaglutide specifically, the regulatory question is largely settled. For the broader GLP-1 class — including the still-investigational compounds — the FDA has signaled that the shortage exception is not going to be a reliable long-term access route.

Side effects

Semaglutide's side effect profile is real and deserves a straightforward conversation.

Gastrointestinal effects are the most common. In the STEP trials, about 44% of participants on semaglutide experienced nausea, 30% diarrhea, 24% vomiting, and 24% constipation. These were predominantly mild to moderate and tended to decrease over time, but they led to treatment discontinuation in about 7% of participants.

The gastroparesis debate has received significant media attention. There have been reports of severe delayed gastric emptying requiring hospitalization. The mechanism is plausible — semaglutide slows gastric emptying by design, and in susceptible individuals this effect may be excessive. The actual incidence of clinically significant gastroparesis appears low in trial data, but post-marketing surveillance is ongoing.

Muscle loss is perhaps the most scientifically important concern. Approximately 40% of weight lost in the STEP trials was lean mass, consistent with any form of caloric restriction. When you are losing 15-17% of body weight, that 40% represents a meaningful absolute amount of muscle. For older adults, this raises sarcopenia concerns. The counter-argument is that percentage-wise, this lean mass loss is no worse than diet-induced weight loss or bariatric surgery, and physical function scores actually improved. A 2024 study showed that participants combining semaglutide with structured resistance training lost primarily fat mass with minimal lean mass reduction. Resistance training during treatment appears to be the answer here.

Other notable effects include gallbladder-related events at higher rates than placebo (likely from rapid weight loss), a theoretical concern about thyroid C-cell tumors from animal studies that human data has not confirmed, and rare reports of pancreatitis.

The overall picture: gastrointestinal effects are common but manageable with dose escalation, gastroparesis is real but uncommon, muscle loss is valid and should be addressed with exercise, and the risk-benefit profile is favorable for most people with obesity. This is a medication with real physiological effects, not a supplement.

Dosage research

The dosage data for semaglutide is more thorough than for almost any peptide in the field. The 2.4mg weekly dose was selected based on Phase 2 dose-ranging studies evaluating doses from 0.05mg to 0.4mg daily. The 2.4mg dose produced the best balance of efficacy and tolerability.

The escalation schedule exists because gastrointestinal side effects are dose-dependent and adaptation occurs over time. Skipping escalation is associated with significantly higher rates of nausea and vomiting.

Some researchers have explored doses above 2.4mg. A Phase 2 study of oral semaglutide at doses up to 50mg daily showed greater weight loss at higher doses, suggesting the dose-response curve has not fully plateaued at currently approved doses. Whether higher injectable doses would produce additional benefit — and at what cost in side effects — remains an active question.

Frequently Asked Questions

How long before you see results?

Most trial participants began seeing measurable weight loss within the first four weeks, coinciding with dose escalation. The most rapid loss typically occurs between weeks 8 and 28, after reaching full dose. Meaningful results — visible changes in how clothes fit and improved metabolic markers — are generally evident by 12-16 weeks on the full dose.

What happens when you stop?

The STEP 4 trial showed that participants who switched to placebo after 20 weeks regained approximately two-thirds of lost weight over the following 48 weeks. Appetite returned to baseline and metabolic improvements began reverting. Most researchers and clinicians now view semaglutide as a long-term treatment, similar to how blood pressure medication manages hypertension without curing it.

Is it safe for people without diabetes?

Yes. The STEP 1, STEP 5, and SELECT trials all enrolled participants without diabetes. Semaglutide did not cause clinically significant hypoglycemia in non-diabetic populations because its insulin-stimulating effect is glucose-dependent — it only promotes insulin release when blood sugar is elevated.

Does semaglutide cause hair loss?

Hair loss (telogen effluvium) has been reported at low rates. This is most likely a consequence of rapid weight loss rather than a direct drug effect — telogen effluvium is a well-documented response to caloric deficit and physiological stress. It is typically temporary and resolves as weight stabilizes. Adequate protein intake during treatment may help.

How does it compare to bariatric surgery?

The STEP trials produced 15-17% average weight loss versus 25-35% for bariatric surgery. But semaglutide avoids surgical risks, is reversible, and can combine with lifestyle modifications. Surgery produces more dramatic results but carries operative risks, requires permanent anatomical changes, and has its own long-term nutritional requirements. For many people, semaglutide is a meaningful pharmacological alternative, particularly for those who are not surgical candidates.

Should you combine semaglutide with exercise?

You should. STEP 3 demonstrated that combining semaglutide with intensive behavioral therapy produced greater weight loss than standard counseling alone. Resistance training in particular mitigates the lean mass loss that is the most commonly cited concern. The research strongly supports a combined approach.